Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study

Documenti analoghi

• Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification
  di: Krishna S. Gunturu, et al.
  Pubblicazione: (2026)
• Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
  di: Maxime Borgeaud, et al.
  Pubblicazione: (2025)
• Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach
  di: Lauren J. Antrim, et al.
  Pubblicazione: (2025)
• Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial
  di: Ling‐Long Tang, et al.
  Pubblicazione: (2025)
• Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial
  di: Lingying Wu, et al.
  Pubblicazione: (2025)